美国基因1a型初治与经治患者接受全口服艾尔巴韦/格拉瑞韦方案治疗前检测NS5A耐药相关多态性的成本效果
研究采用状态转换模型模拟基因1a型丙肝患者接受艾尔巴韦/格拉瑞韦(EBR/GZR)、雷迪帕韦/索磷布韦(LDV/SOF)及3D方案联合或不联合利巴韦林治疗及疾病自然史,估算终身成本(2015年美元)与质量调整生命年(QALY)。结果显示,基线NS5A耐药相关变异(RAVs)检测指导的EBR/GZR治疗较不检测EBR/GZR、3D+RBV或LDV/SOF8获得更多QALY且节省成本。
要点
- 基线RAVs检测指导的EBR/GZR治疗较不检测获得更多QALY且具成本效果。
- 该策略较3D+RBV或LDV/SOF8节省成本,LDV/SOF12较之不具成本效果。
- 在无肝硬化与肝硬化经治患者中,RAVs检测指导的EBR/GZR均为最有效方案。
核心结论
- 在基因1a型初治或经治患者中,EBR/GZR治疗前进行RAVs检测可能是较不检测EBR/GZR、LDV/SOF或3D方案更具成本效果的替代策略。
研究设计与样本
- 采用状态转换模型模拟基因1a型丙肝患者接受EBR/GZR、LDV/SOF和3D方案联合或不联合RBV治疗及疾病自然史,数据来自临床试验与已发表文献,进行基础病例与敏感性分析,成本以2015年美元计。
主要发现
- RAVs检测指导的EBR/GZR治疗较不检测EBR/GZR、3D+RBV或LDV/SOF8获得更多QALY。
- 该策略较3D+RBV或LDV/SOF8节省成本,较不检测EBR/GZR具成本效果。
- LDV/SOF12较EBR/GZR RAVs检测指导策略不具成本效果。
- 在无肝硬化经治患者和肝硬化患者中,RAVs检测指导的EBR/GZR为最有效方案。
- 敏感性分析中RAVs检测在无肝硬化与肝硬化患者中具成本效果的比例分别为48-55%与63-85%。
关键数值与推荐
- 基础病例中RAVs检测指导的EBR/GZR较不检测EBR/GZR、3D+RBV或LDV/SOF8获得更多QALY。
- RAVs检测指导的EBR/GZR较3D+RBV或LDV/SOF8节省成本,较不检测EBR/GZR具成本效果。
- LDV/SOF12较EBR/GZR RAVs检测指导策略不具成本效果。
- 敏感性分析中RAVs检测具成本效果的比例在无肝硬化患者为48-55%,在肝硬化患者为63-85%。
临床怎么用
- 原文结论认为,在基因1a型初治或经治患者中,EBR/GZR治疗前进行RAVs检测可能是较不检测EBR/GZR、LDV/SOF或3D方案更具成本效果的替代策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The presence of baseline NS5A resistance-associated variants (RAVs) impacted treatment response in HCV genotype 1a (GT1a)-infected patients treated with elbasvir/grazoprevir (EBR/GZR) for 12 weeks, but not patients treated with EBR/GZR and ribavirin (RBV) for 16 weeks. AIMS: To assess the cost-effectiveness of baseline testing for NS5A RAVs in EBR/GZR-treated patients compared without testing, and with current treatments for GT1a patients. METHODS: We simulated the course of treatment with EBR/GZR, ledipasvir/sofosbuvir (LDV/SOF) and ombitasvir/paritaprevir/ritonavir+dasabuvir (3D) with or without RBV and natural history of disease of GT1a patients. Treatment-related data from clinical trials were used in a state-transition model of the natural history of chronic HCV GT1a infection and liver disease to project lifetime costs (US$2015) and quality-adjusted life years (QALY). Other clinical and economic inputs were estimated from published sources. We conducted base case and sensitivity analyses. RESULTS: RAVs testing-guided treatment with EBR/GZR resulted in more QALYs than EBR/GZR without testing, 3D+RBV, or LDV/SOF8. This strategy was cost-saving relative to 3D+RBV or LDV/SOF8 and was cost-effective compared with EBR/GZR without testing. LDV/SOF12 was not cost-effective compared with the EBR/GZR RAVs testing-based strategy. Treatment with EBR/GZR guided by RAVs testing is the most effective regimen among treatment-experienced patients without cirrhosis and cirrhotic patients. In sensitivity analysis, RAVs testing was cost-effective in 48-55% and 63-85% among noncirrhotic and cirrhotic patients respectively. CONCLUSIONS: RAVs testing before treatment with EBR/GZR is likely to be a cost-effective alternative to the use of EBR/GZR without testing, LDV/SOF, or 3D among GT1a treatment-naïve or treatment-experienced patients.
引用
- Elbasha EH, Robertson MN, Nwankwo C, et al. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2016. PMID: 27910116. doi:10.1111/apt.13882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。